Vlad Hogenhuis, MD, MBA, on Developing Controllable CAR Ts for Solid Tumors

Video

The chief executive officer of Chimera Bioengineering discussed CBIO-007 and its planned IND submission for colorectal and triple negative breast cancer.

"Chimera’s GOLD technology is rooted in the observation that natural T lymphocytes are adept at controlling when and where they produce potent anti-tumor proteins called cytokines. They have discovered important details about how natural T cells control cytokine production, and have used this understanding to design engineered CAR-T cells that produce extremely potent anti-tumor proteins, like Interleukin-12 (IL-12), only upon interaction with a tumor."

Chimera Bioengineering is aiming to address challenges with chimeric antigen receptor (CAR) T-cell therapies with the use of their GOLD platform technology that arms CAR T therapies with immunomodulatory payloads, such as cytokines like interleukin-12.

Chimera is preparing to submit an investigational new drug application (IND) for its lead candidate CBIO-007for the end of 2023 to be able to evaluate the therapy in a phase 1 trial on the east coast. The therapy is targeted toward the tn-mucin1 antigen, and the phase 1 trial will initially evaluate the therapy in colorectal cancer and triple negative breast cancer.

CGTLive spoke with Vlad Hogenhuis, MD, MBA, chief executive officer and board member, Chimera Bioengineering, to learn more about the company and its technologies. He discussed advantages of the GOLD platform as well as preclinical efficacy if CBIO-007 previously observed.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Nathan Yozwiak, PhD, the head of research at the GCTI
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Related Content
© 2025 MJH Life Sciences

All rights reserved.